GDGregory Scott Day

Gregory Scott Day

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Gregory Scott Day has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Performance of Diagnostic Criteria for Autoimmune Encephalitis in Patients With Suspected Rapidly Progressive Dementia

    by Yoav D. Piura, Anas Elgenidi, Philip W. Tipton, Nihal Satyadev, Neill R. Graff-Radford, Gregory S. Day

  • Education Research: Strengthening the Neurology Pipeline

    by Katherine A. Fu, Christy J. Soares, Justin T. Jordan, Ria Geguera, Michael Urvig, Jose Posas, Aaron S. Zelikovich, Gregory S. Day, Rana R. Said

  • Geographic Variation in Diagnostic Codes Associated With Mild Cognitive Impairment, Alzheimer Disease, and Related Dementias

    by Sahar F. Zafar, Lidia M.V.R. Moura, Brittany Gorham, Esther Ndemo, Stephanie Swanson, Gregory S. Day, Matthew Schelke, Benjamin R. Kummer, Neeta Garg, Andrew Michael Wilson, et al.

    Background and ObjectivesMild cognitive impairment (MCI), Alzheimer disease (AD), and AD-related dementias (ADRD) are growing public health concerns. Regional, demographic, and clinical differences...

  • Open Access

    A shared slowing axis and phenotype-specific rhythms link clinical EEG to FDG-PET dementia phenotypes

    by Nihal Satyadev, Venkatsampath Gogineni, Nick Corriveau-Lecavalier, Gemeng Zhang, Benjamin Brinkmann, Yogatheesan Varatharajah, Gregory S Day, Jennifer L Whitwell, Keith A. Josephs, Kejal Kantarci, et al.

    Early and accurate identification of neurodegenerative disorders has notable implications for treatment and quality of life. Whereas neuroimaging-based biomarkers can accurately identify neurodegenerative subtypes, EEG represents a low-cost alternative that could expand access to dementia care. Here, we investigated whether six data-driven EEG latent factors, derived by nonnegative tensor decomposition of clinical EEGs, differ systematically across FDG-PET-defined neurodegenerative phenotypes. In 455 patients with EEG and FDG-PET acquired within one year of each other, factor expression was compared across 14 diagnostic classes assigned by StateViewer, a validated artificial intelligence framework for FDG-PET interpretation. To separate disease-general severity from phenotype-specific topography, each factor was also regressed on a subject-level slowing index. Finally, we related the factors to regional FDG uptake and to neuropsychological performance (n = 98) and assessed their potential utility for single-subject classification. Four factors reflecting neurophysiological oscillations (posterior alpha, Rolandic beta, frontotemporal delta-theta and posterior theta-slow alpha) varied significantly across phenotypes, with attenuation of faster and augmentation of slower rhythms most pronounced in dementia with Lewy bodies (DLB), dysexecutive Alzheimer disease (AD) and posterior cortical atrophy, whereas factors dominated by eye-movement and muscle artifact showed no robust phenotypic association. Alpha and beta effects were largely attributable to overall slowing, whereas posterior theta-slow alpha became more phenotype-specific after adjustment (eta-squared 0.082 to 0.147), dissociating the Alzheimer disease spectrum from frontotemporal syndromes. The slowing index tracked with an FDG-PET pattern highly associated with DLB across the cohort, irrespective of assigned phenotype (r = 0.51, P < 0.001). Consistent with a model in which dementia phenotypes reflect altered hippocampal-neocortical oscillatory coupling (stochastic latent oscillatory diffusion), frontotemporal delta-theta tracked a limbocortical axis of metabolic pattern expression, rising with neocortical and falling with limbic-predominant involvement, independent of overall slowing and phenotype. Each factor mapped onto a distinct metabolic topography, with frontotemporal delta-theta resembling Alzheimer-type hypometabolism and posterior theta-slow alpha the medial occipital hypometabolism of DLB. In terms of neuropsychological performance, Rolandic beta was associated with executive functions, and frontotemporal delta-theta with memory, visuospatial and global performance. Using these four factors alone, an exploratory logistic regression classifier separated cognitively unimpaired participants from DLB, posterior cortical atrophy, typical AD, and dysexecutive AD (area under the curve > 0.8) but poorly discriminated frontotemporal dementia phenotypes canonically associated with 4-repeat tau. Thus, data-driven decomposition of clinical EEG separates oscillatory activity from artifact into factors that track metabolic phenotype, regional metabolism and cognition, capturing both overall slowing and phenotype-specific patterns. This work informs the further development of scalable, biology-informed EEG-based phenotyping of neurodegenerative disease.

  • Distinct tau PET dynamics in early versus late age-of-onset Alzheimer’s disease

    by Konstantinos Chiotis, Ganna Blazhenets, David N. Soleimani-Meigooni, Paul S. Aisen, Alinda Amuiri, Alireza Atri, Laurel Beckett, Michael Brickhouse, David G. Clark, Jeffrey L. Dage, et al.

    Early-onset Alzheimer’s disease (EOAD) and late-onset AD (LOAD) differ in clinical presentations and rates of progression. We aimed to compare baseline and longitudinal tau positron emission tomography (PET) burden measured with 18 F-flortaucipir and its relationship with clinical variables in amyloid PET–positive, cognitively impaired participants from the Longitudinal Early-Onset Alzheimer’s Disease Study (EOAD; n = 390) and Alzheimer’s Disease Neuroimaging Initiative (LOAD; n = 211). Participants with EOAD showed higher baseline tau PET burden, broader neuroanatomical involvement, and stronger associations of tau PET with amyloid PET and global cognition. Higher baseline tau PET burden in EOAD was independently validated in participants with EOAD from ADNI. Longitudinally, tau PET increased more rapidly in EOAD than in LOAD, independent of amyloid PET and clinical stage. We conclude that earlier age of onset in AD is linked to a more aggressive tauopathy, which in turn is a primary driver of clinical decline.

  • Open Access

    Cerebrospinal Fluid GAD65 ‐Antibody Levels Accurately Identify Relevant Neurological Diseases

    by Max Charles Herman, Maya Marzello, Zoaib Habib Tharwani, Snigdha Kotaru, Yoav D. Piura, Eric Newman, Gregory S. Day, Andrew McKeon, A. Sebastian Lopez‐Chiriboga, Sarosh R. Irani

    Retrospective cohort study to investigate which factors most reliably distinguish incidental GAD65‐antibodies (iGAD65) from true GAD65‐antibody neurological disease (tGAD65). 167 adults with positive serum and CSF GAD65‐antibodies (> 0.02 nmol/L by radioimmunoassay) were classified as tGAD65 or iGAD65, with diagnostic performance of paraclinical parameters compared in discovery and validation cohorts. CSF GAD65‐antibody titers ≥ 1 nmol/L performed best in discovery (AUC 0.956) and validation (AUC 0.949; p = 0.814), with 89.7% sensitivity and 94% specificity for identifying tGAD65. Serum titers > 20 nmol/L and indices of intrathecal synthesis showed lower discriminative ability. Our finding aims to reduce misdiagnosis and identify potential immunotherapy‐responsive diseases.

  • Clinical Factors Associated With Discordant Plasma P-Tau217 and Established Alzheimer Disease Biomarkers

    by Dror Shir, Alicia Algeciras-Schimnich, Yoav D. Piura, Joshua A. Bornhorst, Daniel J. Figdore, Anas Elgenidi, Christian Lachner, Neill R. Graff-Radford, Gregory S. Day

    Background and ObjectivesPlasma phosphorylated tau (p-tau) 217 is increasingly used for Alzheimer disease (AD) diagnosis and treatment decisions but may be discordant with established AD biomarkers...

  • Open Access

    EOAD-Signature Atrophy Predicts Dementia in Early-Onset MCI due to Alzheimer Disease

    by Thiago Paranhos, Yuta Katsumi, Michael Joseph Brickhouse, Ani Eloyan, Ryan Eckbo, Alexander Zaitsev, Anna Du, Renaud La Joie, Maryanne Thangarajah, Alexander Taurone, et al.

    Background and ObjectivesEarly-onset Alzheimer disease (EOAD) is associated with substantial variability in clinical progression, and reliable biomarkers to predict the transition from mild cogniti...

  • Epilepsy as a marker of cognitive decline in cerebral amyloid angiopathy: Evidence from a large multi-institutional cohort

    by Yugant Khand, Sai Krishna Vallamchetla, Anshum Patel, Adrian Safa, Caroline P. Tatit, Gregory S. Day, Michelle P. Lin, Cady K. Block, William O. Tatum, Brin Freund


  • Open Access

    Plasma biomarker signatures in patients with rapidly progressive dementia

    by Lindsey A. Kuchenbecker, Yoav D. Piura, Philip W. Tipton, Yuka A. Martens, Nihal Satyadev, Melissa Petersen, Mercedes Prudencio, Alicia Algeciras‐Schimnich, Daniel J. Figdore, Neill R. Graff‐Radford, et al.

    INTRODUCTION: Overlapping clinical features and results of common diagnostic tests confound early, accurate recognition of distinct causes of rapidly progressive dementia (RPD). Objective, accessible tools are needed to improve etiologic diagnoses and inform counseling and treatment decisions. METHODS: Biomarkers of Alzheimer's disease neuropathology, neuroaxonal injury, neuroinflammation, vascular injury, metabolic dysfunction, and systemic inflammation were measured in plasma from 58 patients with RPD and 40 patients with typically progressive neurodegenerative diseases enrolled in prospective studies of memory and aging. RESULTS: Neuroaxonal injury and neuroinflammation biomarkers were elevated in patients with prion and vascular (versus other) causes of RPD. Markers of systemic inflammation were uniquely elevated in patients with rapidly versus typically progressive neurodegenerative diseases. Higher phosphorylated tau (p‐tau)217 and p‐tau181 levels, and lower amyloid beta 42/40 levels, were nominally associated with treatment–non‐responsive causes of RPD. DISCUSSION: Blood biomarkers may inform biological heterogeneity underlying RPD with potential diagnostic and therapeutic implications pending validation in larger longitudinal cohorts.